Active Pharmaceutical Ingredients (API) Market – Industry Analysis and Forecast (2019-2027)_by Synthesis Type, by Drug Type, by Manufacturer Type, by Therapeutic Area, and by Geography

Active Pharmaceutical Ingredients (API) Market size was valued at USD 179.77 Bn in 2019 and is projected to reach USD XX Bn by 2027 at a CAGR of XX % during the forecast period. The report includes an analysis of the impact of COVID-19 lockdown on the revenue of market leaders, followers, and disruptors. Since the lockdown was implemented differently in various regions and countries; the impact of the same is also seen differently by regions and segments. The report has covered the current short-term and long-term impact on the market, and it would help the decision-makers to prepare the outline and strategies for companies by region.

Active Pharmaceutical Ingredients Market

To know about the Research Methodology :- Request Free Sample Report

Active Pharmaceutical Ingredients (API) Market Dynamics:

An active pharmaceutical ingredient is a biologically active portion of a pharmaceutical drug intended to perform certain pharmacological actions or have prominent effects for the diagnosis, cure, treatment, or prevention of chronic and acute diseases. The rising prevalence of chronic diseases and increasing uptake of biopharmaceuticals is expected to majorly drive the market growth. As per data published by the World Health Organization (WHO), chronic disease prevalence is anticipated to rise by 57.0% by the year 2020. The number of people suffering from diabetes in developing countries was 84.0 million in 1995, which is projected to increase by 2.5-fold to 228.0 million in 2027. Chronic diseases include diabetes, obesity, and cardiovascular diseases, cancer, neurological diseases, and other diseases; the rise in prevalence of these diseases are augmenting the demand for treatment that may support the market growth over the forecast period. Furthermore, augmented demand for rapid-acting & efficient drugs and the emergence of innovative drug manufacturing facilities are expected to assist in market growth during the forecast period. Loss of drug exclusivity is impeding revenue growth. Patent expiration is accountable for the huge loss for pharmaceutical firms in terms of revenue, which is anticipated to impede the market growth during the forecast period.

Active Pharmaceutical Ingredients (API) Market Segment Analysis:

The biotech APIs segment is expected to register comparatively higher CAGR over the forecast period owing to high R&D for novel biosimilar drugs, escalating demand for protein-based therapeutics, and rising key traditional manufacturers’ focus toward biological drugs. A surge in prescription rates and drug prices coupled with higher spending on R&D activities are expected to contribute to the dominance of the branded/innovative drugs segment. The merchant manufacturers segment is expected to witness lucrative market growth. The worldwide rising outsourcing of API/drug molecule formulation from drug manufacturers in order to eliminate the need for heavy investment in manufacturing processes has increased the growth of the segment.

Active Pharmaceutical Ingredients (API) Market Regional Insights:

North America is expected to hold a substantial market share over the next ten years owing to the presence of favorable government initiatives, changing lifestyles leads to the development of diseases, rising investment in R&D, and technological developments in drug manufacturing processes.

Active Pharmaceutical Ingredients Market Research Methodology:

The market is estimated by triangulation of data points obtained from various sources and feeding them into a simulation model created individually for each market. The data points are obtained from paid and unpaid sources along with paid primary interviews with key opinion leaders (KOLs) in the market. KOLs from both, demand and supply sides were considered while conducting interviews to get an unbiased idea of the market. This exercise was done at a country level to get a fair idea of the market in countries considered for this study. Later this country-specific data was accumulated to come up with regional numbers and then arrive at the market value for the active pharmaceutical ingredients market.

Active Pharmaceutical Ingredients Market Key Target Audience:

• Healthcare companies • Corporate healthcare entities • Government agencies • Market research and consulting firms • Venture capitalists • Technical Students

Active Pharmaceutical Ingredients (API) Market, Key Highlights:

• Active Pharmaceutical Ingredients (API) Market analysis and forecast, in terms of value. • Comprehensive study and analysis of market drivers, restraints and opportunities influencing the growth of the Active Pharmaceutical Ingredients (API) Market • Active Pharmaceutical Ingredients (API) Market segmentation on the basis of type, source, end-user, and region (country-wise) has been provided. • Active Pharmaceutical Ingredients (API) Market strategic analysis with respect to individual growth trends, future prospects along with the contribution of various sub-market stakeholders have been considered under the scope of study. • Active Pharmaceutical Ingredients (API) Market analysis and forecast for five major regions namely North America, Europe, Asia Pacific, the Middle East & Africa (MEA) and Latin America along with country-wise segmentation. • Profiles of key industry players, their strategic perspective, market positioning and analysis of core competencies are further profiled. • Competitive developments, investments, strategic expansion and competitive landscape of the key players operating in the Active Pharmaceutical Ingredients (API) Market are also profiled. The report has considered the base year of 2019 and past four years trend. 2020 figures are at actuals, however due to different dynamics of year 2020, market forecast is not only dependent upon 2020, but on the basis of 2016-2020.

Scope of the Active Pharmaceutical Ingredients Market Report: Inquire before buying

Active Pharmaceutical Ingredients Market, by Synthesis Type

• Biotech • Monoclonal Antibodies • Recombinant Proteins • Vaccines • Synthetic

Active Pharmaceutical Ingredients Market, by Drug Type

• Branded Drugs • Generic Drugs • Over-the-counter (OTC) Drugs

Active Pharmaceutical Ingredients Market, by Manufacturer Type

• Captive Manufacturers • Merchant Manufacturers

Active Pharmaceutical Ingredients Market, by Therapeutic Area

• Cardiology • Pulmonology • Opthalmology • Neurology • Oncology • Orthopedics • Others

Active Pharmaceutical Ingredients Market, by Geography

• North America • U.S. • Canada • Europe • UK • Germany • France • Italy • Spain • Rest of Europe • Asia Pacific • Japan • China • India • Rest of Asia Pacific • Latin America • Brazil • Mexico • Rest of Latin America • MEA • South Africa • Saudi Arabia • Rest of MEA

Active Pharmaceutical Ingredients Market Geographic Analysis:

• Breakdown of North America Active Pharmaceutical Ingredients Market • Breakdown of Europe Active Pharmaceutical Ingredients Market • Breakdown of Asia Pacific Active Pharmaceutical Ingredients Market • Breakdown of Latin America Active Pharmaceutical Ingredients Market • Breakdown of MEA Active Pharmaceutical Ingredients Market

Active Pharmaceutical Ingredients Market, Key Players

• AbbVie Inc. • Bristol-Myers Squibb Company • Boehringer Ingelheim GmbH • Cipla Inc. • Merck & Co., Inc. • Eli Lilly and Company • Mylan N.V. • Teva Active Pharmaceuticals Industries Ltd. • Aurobindo Pharma • Sun Pharmaceutical Industries, Ltd. • Dr. Reddy’s Laboratories Ltd. • Albemarle Corporation • Viatris Inc. • Pfizer Inc. • Novartis International AG • F. Hoffmann-La Roche AG • AstraZeneca • GlaxoSmithKline plc • Actavis plc • Hospira Inc. • BASF SE.

Available Customization:

Maximize Market Research offers customization of reports according to the specific requirement of our clients.

Active Pharmaceutical Ingredients Market

1. EXECUTIVE SUMMARY 2. RESEARCH METHODOLOGY 2.1. Market Definition 2.2. Market Scope 2.3. Data Sources 3. MARKET VARIABLES & SCOPE 3.1. Market Segmentation & Scope 3.2. Market Driver Analysis 3.3. Market Restraint Analysis 3.4. Penetration & Growth Prospect Mapping 3.5. Market SWOT Analysis, By Factor (political & legal, economic, and technological) 3.6. Porter’s Five Forces Industry Analysis 3.7. Market Value Chain Analysis 4. SYNTHESIS TYPE ESTIMATES & TREND ANALYSIS (2019 – 2026) 4.1. Active Pharmaceutical Ingredients Market: Synthesis Type Movement Analysis 4.2. Biotech 4.2.1. Biotech market, 2019 – 2026 (USD billion) 4.2.2. Monoclonal antibodies 4.2.2.1. Monoclonal antibodies market, 2019 – 2026 (USD billion) 4.2.3. Recombinant proteins 4.2.3.1. Recombinant proteins market, 2019 – 2026 (USD billion) 4.2.4. Vaccines 4.2.4.1. Vaccines market, 2019 – 2026 (USD billion) 4.3. Synthetic 4.3.1. Synthetic market, 2019 – 2026 (USD billion) 5. DRUG TYPE ESTIMATES & TREND ANALYSIS (2019 – 2026) 5.1. Active Pharmaceutical Ingredients Market: Drug Type Movement Analysis 5.2. Branded/Innovative Drugs 5.2.1. Branded/Innovative drugs market, 2019 – 2026 (USD billion) 5.3. Generic Drugs 5.3.1. Generic drugs market, 2019 – 2026 (USD billion) 5.4. Over-the-counter (OTC) Drugs 5.4.1. Over-the-counter market, 2019 – 2026 (USD billion) 6. MANUFACTURER TYPE ESTIMATES & TREND ANALYSIS (2019 – 2026) 6.1. Active Pharmaceutical Ingredients Market: Manufacturer Type Movement Analysis 6.2. Captive Manufacturers 6.2.1. Captive manufacturers market, 2019 – 2026 (USD billion) 6.3. Merchant Manufacturers 6.3.1. Merchant manufacturers market, 2019 – 2026 (USD billion) 7. THERAPEUTIC AREA ESTIMATES & TREND ANALYSIS (2019 – 2026) 7.1. Active Pharmaceutical Ingredients Market: Therapeutic Area Movement Analysis 7.2. Cardiology 7.2.1. Cardiology market, 2019 – 2026 (USD billion) 7.3. Pulmonology 7.3.1. Pulmonology market, 2019 – 2026 (USD billion) 7.4. Oncology 7.4.1. Oncology market, 2019 – 2026 (USD billion) 7.5. Neurology 7.5.1. Neurology market, 2019 – 2026 (USD billion) 7.6. Ophthalmology 7.6.1. Ophthalmology market, 2019 – 2026 (USD billion) 7.7. Orthopedics 7.7.1. Orthopedics market, 2019 – 2026 (USD billion) 7.8. Others 7.8.1. Others market, 2019 – 2026 (USD billion) 8. REGIONAL ESTIMATES & TREND ANALYSIS BY SYNTHESIS TYPE, DRUG TYPE, MANUFACTURER TYPE, THERAPEUTIC AREA, (2019 – 2026) 8.1. Active Pharmaceutical Ingredients Market Share By Region, 2019 & 2026 8.2. North America 8.2.1. North America active pharmaceutical ingredients market, 2019 – 2026 (USD billion) 8.2.2. U.S. 8.2.2.1. U.S. active pharmaceutical ingredients market, 2019 – 2026 (USD billion) 8.2.3. Canada 8.2.3.1. Canada active pharmaceutical ingredients market, 2019 – 2026 (USD billion) 8.3. Europe 8.3.1. Europe active pharmaceutical ingredients market, 2019 – 2026 (USD billion) 8.3.2. UK 8.3.2.1. UK active pharmaceutical ingredients market, 2019 – 2026 (USD billion) 8.3.3. Germany 8.3.3.1. Germany active pharmaceutical ingredients market, 2019 – 2026 (USD billion) 8.3.4. France 8.3.4.1. France active pharmaceutical ingredients market, 2019 – 2026 (USD billion) 8.3.5. Italy 8.3.5.1. Italy active pharmaceutical ingredients market, 2019 – 2026 (USD billion) 8.3.6. Spain 8.3.6.1. Spain active pharmaceutical ingredients market, 2019 – 2026 (USD billion) 8.3.7. Rest of Europe 8.3.7.1. Rest of Europe active pharmaceutical ingredients market, 2019 – 2026 (USD billion) 8.4. Asia Pacific 8.4.1. Asia Pacific active pharmaceutical ingredients market, 2019 – 2026 (USD billion) 8.4.2. Japan 8.4.2.1. Japan active pharmaceutical ingredients market, 2019 – 2026 (USD billion) 8.4.3. China 8.4.3.1. China active pharmaceutical ingredients market, 2019 – 2026 (USD billion) 8.4.4. India 8.4.4.1. India active pharmaceutical ingredients market, 2019 – 2026 (USD billion) 8.4.5. Rest of Asia Pacific 8.4.5.1. Rest of Asia Pacific active pharmaceutical ingredients market, 2019 – 2026 (USD billion) 8.5. Latin America 8.5.1. Latin America active pharmaceutical ingredients market, 2019 – 2026 (USD billion) 8.5.2. Mexico 8.5.2.1. Mexico active pharmaceutical ingredients market, 2019 – 2026 (USD billion) 8.5.3. Brazil 8.5.3.1. Brazil active pharmaceutical ingredients market, 2019 – 2026 (USD billion) 8.5.4. Rest of Latin America 8.5.4.1. Rest of Latin America active pharmaceutical ingredients market, 2019 – 2026 (USD billion) 8.6. MEA 8.6.1. MEA active pharmaceutical ingredients market, 2019 – 2026 (USD billion) 8.6.2. South Africa 8.6.2.1. South Africa active pharmaceutical ingredients market, 2019 – 2026 (USD billion) 8.6.3. Saudi Arabia 8.6.3.1. Saudi Arabia active pharmaceutical ingredients market, 2019 – 2026 (USD billion) 8.6.4. Rest of MEA 8.6.4.1. Rest of active pharmaceutical ingredients market, 2019 – 2026 (USD billion) 9. MARKET COMPETITION ANALYSIS 9.1. Strategy Framework 9.2. Company Profiles 9.2.1. AbbVie Inc. 9.2.1.1. Company Overview 9.2.1.2. Financial Performance 9.2.1.3. Product Benchmarking 9.2.1.4. Strategic Initiatives 9.2.2. Bristol-Myers Squibb Company 9.2.2.1. Company Overview 9.2.2.2. Financial Performance 9.2.2.3. Product Benchmarking 9.2.2.4. Strategic Initiatives 9.2.3. Boehringer Ingelheim GmbH 9.2.3.1. Company Overview 9.2.3.2. Financial Performance 9.2.3.3. Product Benchmarking 9.2.3.4. Strategic Initiatives 9.2.4. Cipla Inc. 9.2.4.1. Company Overview 9.2.4.2. Financial Performance 9.2.4.3. Product Benchmarking 9.2.4.4. Strategic Initiatives 9.2.5. Merck & Co., Inc. 9.2.5.1. Company Overview 9.2.5.2. Financial Performance 9.2.5.3. Product Benchmarking 9.2.5.4. Strategic Initiatives 9.2.6. Eli Lilly and Company 9.2.6.1. Company Overview 9.2.6.2. Financial Performance 9.2.6.3. Product Benchmarking 9.2.6.4. Strategic Initiatives 9.2.7. Mylan N.V. 9.2.7.1. Company Overview 9.2.7.2. Financial Performance 9.2.7.3. Product Benchmarking 9.2.7.4. Strategic Initiatives 9.2.8. Teva Active Pharmaceuticals Industries Ltd. 9.2.8.1. Company Overview 9.2.8.2. Financial Performance 9.2.8.3. Product Benchmarking 9.2.8.4. Strategic Initiatives 9.2.9. Aurobindo Pharma 9.2.9.1. Company Overview 9.2.9.2. Financial Performance 9.2.9.3. Product Benchmarking 9.2.9.4. Strategic Initiatives 9.2.10. Sun Pharmaceutical Industries, Ltd. 9.2.10.1. Company Overview 9.2.10.2. Financial Performance 9.2.10.3. Product Benchmarking 9.2.10.4. Strategic Initiatives 9.2.11. Dr. Reddy’s Laboratories Ltd. 9.2.11.1. Company Overview 9.2.11.2. Financial Performance 9.2.11.3. Product Benchmarking 9.2.11.4. Strategic Initiatives 9.2.12. Albemarle Corporation 9.2.12.1. Company Overview 9.2.12.2. Financial Performance 9.2.12.3. Product Benchmarking 9.2.12.4. Strategic Initiatives 9.2.13. Viatris Inc. 9.2.14. Pfizer Inc. 9.2.15. Novartis International AG 9.2.16. F. Hoffmann-La Roche AG 9.2.17. AstraZeneca 9.2.18. GlaxoSmithKline plc 9.2.19. Actavis plc 9.2.20. Hospira Inc. 9.2.21. BASF SE.

About This Report

Report ID 1816
Category Healthcare
Published Date July 2019
Updated Date March 2021
Contact Us